Caris Life Sciences
750 West John Carpenter Freeway
Suite 800
Irving
Texas
75039
United States
Website: http://www.carislifesciences.com/
231 articles with Caris Life Sciences
-
Caris Life Sciences Announces Appointment of Lloyd B. Minor to Board of Directors
11/19/2021
Caris Life Sciences announced today the appointment of Lloyd B. Minor , M.D. to the Caris Board of Directors, effective immediately.
-
Caris Precision Oncology Alliance Announces the Addition of Columbia University Irving Medical Center to Its Collaborative Network of Precision Medicine Experts
11/18/2021
Caris Life Sciences® announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris' Precision Oncology Alliance™ (POA).
-
Caris' Precision Oncology Alliance Welcomes The Georgia Cancer Center at Augusta University
11/11/2021
Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that the Georgia Cancer Center at Augusta University has joined Caris' Precision Oncology Alliance™.
-
Caris Precision Oncology Alliance Partners with the National Cancer Institute, Part of the National Institutes of Health, to Expand Collaborative Clinical Research Efforts
10/29/2021
Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced that the Caris Precision Oncology Alliance™ and NCI's Center for Cancer Research will collaborate on precision medicine research initiatives.
-
Caris Life Sciences and Ono Pharmaceutical Announce Strategic Collaboration Leveraging Caris' Novel, Blood-Based cNAS Molecular Profiling Assay Across Several Ono Clinical Studies
10/14/2021
Caris Life Sciences® and Ono Pharmaceutical Co., Ltd. announced a strategic collaboration to leverage Caris' best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing assay, across several studies beginning later this year.
-
Andreas Tsukada Joins Caris Life Sciences as President of Japanese Operations and Head of International
10/12/2021
Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced that Andreas S. Tsukada has joined the Company as Senior Vice President, President of Japanese Operations and Head of International.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration
10/7/2021
Caris Life Sciences® and ESSA Pharma Inc. announced a Precision Development program to support ESSA's ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer failing current standard-of-care therapies.
-
Caris Life Sciences Announces Appointment of Mike Weinstein, Medical Technology Executive and Wall Street Veteran, as Chief Financial Officer
10/6/2021
Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, announced the appointment of Mike Weinstein as Executive Vice President and Chief Financial Officer.
-
Dr. Milan Radovich, Ph.D., Joins Caris Life Sciences as Chief Precision Medicine Officer
9/21/2021
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced that Milan Radovich, Ph.D., has joined Caris as the Company's Chief Precision Medicine Officer.
-
Caris Life Sciences to Present New Data at ESMO 2021 Highlighting Gene Expression in Colorectal Cancer - Comprehensive Profiling and Clinical Value
9/15/2021
Caris Life Sciences® announced results from a study highlighting a strong association between CCR5/CCL5 gene expression and distinct molecular features including Consensus Molecular Subtype, tumor mutational burden, lymphocyte infiltration in the tumor microenvironment, as well as patient outcome, and treatment benefit in Colorectal Cancer.
-
Caris' Precision Oncology Alliance Welcomes The O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham
8/26/2021
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced that the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham has joined Caris' Precision Oncology Alliance™.
-
Caris Life Sciences and Elevation Oncology Announce Joint Discovery and Development Collaboration Focused on Oncogenic Fusions and Driver Mutations
6/15/2021
Caris Life Sciences® and Elevation Oncology announced a strategic collaboration to jointly identify oncogenic fusions and mutations that are driver alterations.
-
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
-
New Research from Caris Life Sciences Finds Immunotherapy Resistance in Leiomyosarcoma
6/4/2021
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, to present findings that provide a deeper understanding of how immunotherapies affect leiomyosarcoma, a rare cancer that affects smooth muscle tissue, through the use of whole exome and whole transcriptome sequencing.
-
Caris Life Sciences and National Cancer Center Japan Announce Exclusive Collaboration to Launch The SCRUM-Japan MONSTAR-SCREEN-2 Trial
5/20/2021
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced they have entered into an exclusive collaboration agreement with the National Cancer Center Japan to provide Caris' comprehensive molecular profiling in MONSTAR-SCREEN-2 of SCRUM-Japan, the largest cancer genomic screening consortium in Japan.
-
ASCO 2021 Showcases the Impact of Caris' Molecular Science Data in Advancing Cancer Care
5/18/2021
Over 20 studies to be presented at ASCO, featuring data from leading cancer research institutions across the U.S. in partnership with Caris Life Sciences, highlighting Caris' innovative technology and robust clinico-genomic database.
-
Sidney Kimmel Cancer Center at Jefferson Health Joins Caris Life Sciences' Precision Oncology Alliance
5/14/2021
National Cancer Institute-designated Sidney Kimmel Cancer Center partners with Caris' collaborative network of oncology experts to advance personalized cancer treatments
-
The company has raised approximately $1.3 billion in external financing over the past three years, including $310 million in 2020.
-
Caris Life Sciences Announces Appointment of Joseph E. Gilliam to Board of Directors
4/28/2021
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced the appointment of Joseph E. Gilliam to the Caris Board of Directors, effective April 12, 2021.